Gowoon Yang

Gowoon Yang

Auto-generated profile, based on publicly available information

Gowoon Yang

Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2023 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
GYGowoon Yang
Gowoon Yang
HYHong In Yoon
Hong In Yoon
JLJoongyo Lee
Joongyo Lee
JKJihun Kim
Jihun Kim
HKHojin Kim
Hojin Kim
KKKyung Hwan Kim
Kyung Hwan Kim

12 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
GYGowoon Yang
Gowoon Yang
CLChang Young Lee
Chang Young Lee
EKEun Young Kim
Eun Young Kim
YLYong Chan Lee
Yong Chan Lee
MHMin Hee Hong
Min Hee Hong
JCJaeho Cho
Jaeho Cho
Introduction: We aimed to identify the role of radiotherapy (RT) in the treatment of thymic carcinoma as well as the optimal RT target volume. Materials and Methods: This single-institution retrospective study included 116 patients diagnosed with thymic carcinoma between November 2006 and December 2021 who received multimodal treatment including RT with or without surgery or chemotherapy. Seventy-nine patients (68.1%) were treated with postoperative RT, 17 patients (14.7%) with preoperative RT, 11 patients (9.5%) with definitive RT, and nine patients (7.8%) with palliative RT. The target volume was defined as the tumor bed or gross tumor with margin, and selective irradiation of the regional nodal area was performed when involved. Results: With a median follow-up of 37.0 (range, 6.7–174.3) months, the 5-year overall survival (OS), progression-free survival, and local recurrence-free survival rates were 75.2%, 47.7% and 94.7%, respectively. The 5-year OS was 51.9% in patients with unresectable disease. Overall, 53 recurrences were observed, of which distant metastasis was the most common pattern of failure (n = 32, 60.4%) after RT. No isolated infield or marginal failures were observed. Thirty patients (25.8%) who had lymph node metastases at the initial diagnosis had regional nodal areas irradiated. There was no lymph node failure inside the RT field. A tumor dimension of ≥5.7 cm (hazard ratio [HR] 3.01; 95% confidence interval [CI] 1.25–7.26; p = 0.030) and postoperative RT (HR 0.20; 95% CI 0.08–0.52; p = 0.001) were independently associated with OS. Intensity-modulated-RT-treated patients developed less overall toxicity (p < 0.001) and esophagitis (p < 0.021) than three-dimensional-conformal-RT-treated patients. Conclusions: A high local control rate was achieved with RT in the primary tumor sites and involved lymph node area in the treatment of thymic carcinoma. A target volume confined to the tumor bed or gross tumor plus margin with the involved lymph node stations seems reasonable. The advanced RT techniques with intensity-modulated RT have led to reduced RT-related toxicity.

1 January 2021 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
HKHyun Ju Kim
Hyun Ju Kim
JCJaehee Chun
Jaehee Chun
TKTae Hyung Kim
Tae Hyung Kim
GYGowoon Yang
Gowoon Yang
SSSang Joon Shin
Sang Joon Shin
WKWoong Sub Koom
Woong Sub Koom
Kim HJ, et al. Yonsei Med J. 2021 Jul;62(7):569-576. https://doi.org/10.3349/ymj.2021.62.7.569

1 January 2024 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
GYGowoon Yang
Gowoon Yang
JKJun Won Kim
Jun Won Kim
ILIk Jae Lee
Ik Jae Lee
JJJoon Jeong
Joon Jeong
SASung Gwe Ahn
Sung Gwe Ahn
YCYeona Cho
Yeona Cho
Yang G, et al. Yonsei Med J. 2024 Mar;65(3):129-136. https://doi.org/10.3349/ymj.2023.0229

15 January 2024 in Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
GYGowoon Yang
Gowoon Yang
KKKyung Hwan Kim
Kyung Hwan Kim
CLChang Geol Lee
Chang Geol Lee
MHMin Hee Hong
Min Hee Hong
HKHye Ryun Kim
Hye Ryun Kim
HYHong In Yoon
Hong In Yoon
This study aimed to determine the role of local ablative radiotherapy (LART) in oligometastatic/oligoprogressive lung adenocarcinoma. Patients (n=176) with oligometastatic lung adenocarcinoma treated with LART were identified, and those treated with LART at the initial diagnosis of synchronous oligometastatic disease (OMD group) or treated with LART when they presented with repeat oligoprogression (OPD group) were included. In the OMD group (n=54), the 1- and 3-year progression-free survival (PFS) were 50.9% and 22.5%, respectively, whereas the 1- and 3-year overall survival in the OPD group were 75.9% and 58.1%, respectively. Forty-one patients (75.9%) received LART at all gross disease sites. Tyrosine kinase inhibitor (TKI) use and all-metastatic site LART were significant predictors of higher PFS (p=0.018 and p=0.046, respectively). In patients treated with TKIs at the time of LART (n=23) and those treated with all-metastatic site LART, the 1-year PFS was 86.7%, while that of patients not treated with all-metastatic site LART was 37.5% (p=0.006). In the OPD group (n=122), 67.2% of the patients (n=82) maintained a systemic therapy regimen after LART. The cumulative incidence of changing systemic therapy was 39.6%, 62.9%, and 78.5% at 6 months, 1 year, and 2 years after LART, respectively. Aggressive LART can be an option to improve survival in patients with oligometastatic disease. Patients with synchronous oligometastatic disease receiving TKI and all-metastatic site LART may have improved PFS. In patients with repeat oligoprogression, LART might potentially extend survival by delaying the need to change the systemic treatment regimen.